Shwetha G null, Kanchana B.K null, Nair Athira T null
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
Methodology: A total of 100 patients presenting with conjunctivitis were thoroughly examined and patients with viral conjunctivitis were included in the study. Study data included visual acuity, slit lamp examination and follow up after 5 days. Patients were given conservative treatment like cold compression, lubricating eye drops, anti-histamines, Moxifloxacin Low potency steroid combination eye drops, Moxifloxacin eye drops, Tobramycin eye drops and Chloramphenicol eye ointment according to the severity of the conjunctivitis and corneal involvement, for 3-7 days according to the underlying etiology and severity of the disease. Results: In cases with, mild conjunctivitis cold compression, topical lubricants and topical anti histamines and topical antibiotics eye drops were advised, which showed symptomatic relief. In patients with severe inflammation, Moxifloxacin and low potency steroid combination eye drops showed better results. Topical Steroids were avoided in 3% of the study population who developed superficial punctate keratitis. Conclusion: It’s a self-limiting disease. There is need to educate people about personal hygiene and adverse effects of sharing of eye drops and self-medication.
No records found.
Taklikar AR, Shwetha G, Kanchana BK, et al. Eye flu epidemic: modes of presentation and deciding its management. Ophthalmol Allied Sci. 2023;9(3):41-44.
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
| Received | Accepted | Published |
|---|---|---|
| August 23, 2023 | October 04, 2023 | November 30, 2023 |
Monday 27 July 2026, 12:50:10 (IST)
Download citation
Highlight selected keywords in the article text.
| Received | August 23, 2023 |
| Accepted | October 04, 2023 |
| Published | November 30, 2023 |
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.